Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLNNASDAQ:CURRNASDAQ:FLGCOTCMKTS:NRIFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/ACURRCurrenc Group$0.36-1.4%$0.94$0.33▼$7.08$16.75M-0.492.09 million shs3.33 million shsFLGCFlora Growth$0.72-0.3%$0.63$0.42▼$2.11$16.20M2.04274,411 shs147,239 shsNRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-75.97%CURRCurrenc Group0.00%-22.59%-44.10%-79.08%+35,989,900.00%FLGCFlora Growth0.00%-7.47%+10.07%+15.81%-29.61%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACURRCurrenc GroupN/AN/AN/AN/AN/AN/AN/AN/AFLGCFlora Growth1.9707 of 5 stars3.33.00.00.00.00.80.6NRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/ACURRCurrenc Group 3.50Strong Buy$3.50872.49% UpsideFLGCFlora Growth 2.50Moderate Buy$4.00457.10% UpsideNRIFFNuvo Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09CURRCurrenc Group$46.44M0.36N/AN/A($0.90) per share-0.40FLGCFlora Growth$59.51M0.27N/AN/A$0.31 per share2.32NRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/ACURRCurrenc Group-$39.47MN/A0.00∞N/AN/AN/A-38.11%7/14/2025 (Estimated)FLGCFlora Growth-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/ALatest CURR, NRIFF, ASLN, and FLGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CURRCurrenc Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/13/2025Q1 2025FLGCFlora Growth-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 million4/14/2025Q4 2024CURRCurrenc Group-$0.04-$0.70-$0.66-$0.70$10.50 million$11.07 million3/24/2025Q4 2024FLGCFlora Growth-$0.11-$0.42-$0.31-$0.45$13.55 million$13.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACURRCurrenc GroupN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05CURRCurrenc GroupN/A0.610.61FLGCFlora Growth0.881.050.67NRIFFNuvo Pharmaceuticals5.272.672.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%CURRCurrenc Group56.01%FLGCFlora Growth36.01%NRIFFNuvo PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%CURRCurrenc Group17.80%FLGCFlora Growth12.56%NRIFFNuvo PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableCURRCurrenc Group246.53 million38.25 millionN/AFLGCFlora Growth28022.57 million19.73 millionNot OptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionableCURR, NRIFF, ASLN, and FLGC HeadlinesRecent News About These Companies4 Best Home Oxygen Concentrators Of 2024February 14, 2024 | forbes.comAbout NUVOApril 2, 2023 | nuvo.netEPA Expresses Support for State-level Permitting for Carbon Capture and Sequestration ProjectsJanuary 15, 2023 | nuvo.netMiravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South KoreaJuly 29, 2021 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryThe Market’s Silent Warning: What Bonds and Gold RevealBy Gabriel Osorio-Mazilli | June 6, 2025View The Market’s Silent Warning: What Bonds and Gold RevealAs Gold Surges, Albemarle Stock May Be the Next to PopBy Gabriel Osorio-Mazilli | June 10, 2025View As Gold Surges, Albemarle Stock May Be the Next to PopWhy Visa's Innovation Engine Keeps It a Top Portfolio PickBy Jeffrey Neal Johnson | June 6, 2025View Why Visa's Innovation Engine Keeps It a Top Portfolio PickCURR, NRIFF, ASLN, and FLGC Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 06/18/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Currenc Group NASDAQ:CURR$0.36 -0.01 (-1.37%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$0.36 +0.00 (+0.03%) As of 06/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.Flora Growth NASDAQ:FLGC$0.72 0.00 (-0.28%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.74 +0.02 (+3.06%) As of 06/18/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.Nuvo Pharmaceuticals OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
